Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 8/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19181227 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL13163960 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL21770659 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL29231967 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL29246157 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL1584687 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL7918399 | 1.00 | NR1H2 (0.47) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL30104010 | 0.91 | NR1H2 (0.44) | NR1H2SRCUCHL1CHRM2CHRM1 | |
| SCHEMBL24251931 | 0.88 | NR1H2 (0.40) | NR1H2UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL24739166 | 0.88 | NR1H2 (0.47) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4219478-B1 | METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-112996795-B | Fused tricyclic derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-113227103-B | Trisubstituted heteroaryl derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230312483-A1 | Amino Pyrimidine Derivatives | NOVARTIS AG (CH) | 2023-10-05 | — | — | US | disclosed |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2011079327-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152068-A1 | NOVEL AMINO PYRIMIDINE DERIVATIVES | BTK, LCK, JAK1 | NR1H2 3676/4885SRC 22/4885UCHL1 4717/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | NR1H2 3543/4885SRC 3128/4885UCHL1 4354/4885 |
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | NR1H2 2156/4885SRC 1073/4885UCHL1 4517/4885 |
| US-20230312483-A1 | Amino Pyrimidine Derivatives | BTK, LCK, JAK1 | NR1H2 3412/4885SRC 20/4885UCHL1 4739/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SRC 628/4885UCHL1 2608/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | NR1H2 2154/4885SRC 1/4885UCHL1 3481/4885 |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | NR1H2 160/4885SRC 2794/4885UCHL1 4794/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SRC 628/4885UCHL1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.